Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20817264 | 1.00 | PYGB (0.41) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL23066316 | 1.00 | PYGB (0.41) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL31206852 | 0.90 | CA12 (0.45) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL22346509 | 0.89 | CA12 (0.48) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL670576 | 0.87 | PYGB (0.44) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL2848040 | 0.87 | PYGB (0.44) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL4006332 | 0.87 | PYGB (0.44) | PYGBCA2CA9CA12CA1 | |
| SCHEMBL309481 | 0.81 | CA1 (0.47) | PYGBCA2CA9CA1GAA | |
| SCHEMBL4345382 | 0.81 | CA1 (0.47) | PYGBCA2CA9CA1GAA | |
| SCHEMBL2169970 | 0.81 | CA1 (0.47) | PYGBCA2CA9CA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006542-A1 | ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-ROR1 ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023244517-A1 | INTERLEUKIN-2 PRODRUGS | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4143233-A1 | METHODS OF PRODUCING FULL-LENGTH ANTIBODIES USING E.COLI | Sutro Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4139340-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | Merck Sharp & Dohme LLC (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220127630-A1 | Brassica Plants Producing Elevated Levels of Polyunsaturated Fatty Acids | CARGILL, INCORPORATED (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3980423-A1 | 5H-PYRROLO[3,2-D]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3962951-A1 | ANTI-BCMA ANTIBODY CONJUGATES | Sutro Biopharma, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021222719-A1 | METHODS OF PRODUCING FULL-LENGTH ANTIBODIES USING E.COLI | SUTRO BIOPHARMA, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021216478-A1 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER | MERCK SHARP & DOHME CORP. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-1771573-A2 | BIOSYNTHETIC POLYPEPTIDES UTILIZING NON-NATURALLY ENCODED AMINO ACIDS | AMBRX, INC. (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006133088-A2 | IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES | AMBRX, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006133089-A2 | IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES | AMBRX, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006132969-A2 | INCORPORATION OF NON-NATURALLY ENCODED AMINO ACIDS INTO PROTEINS | AMBRX, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1718339-A2 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1718664-A2 | MODIFIED HUMAN FOUR HELICAL BUNDLE POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006091231-A2 | BIOSYNTHETIC POLYPEPTIDES UTILIZING NON-NATURALLY ENCODED AMINO ACIDS | AMBRX, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006073846-A2 | METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE | AMBRX, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005074524-A2 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005074650-A2 | MODIFIED HUMAN FOUR HELICAL BUNDLE POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127630-A1 | Brassica Plants Producing Elevated Levels of Polyunsaturated Fatty Acids | FADS2, ELOVL3, SCD | PYGB 1774/4885CA2 4157/4885CA9 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.